Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDexbrompheniramine
Identification
- Name
- Dexbrompheniramine
- Accession Number
- DB00405 (APRD00770)
- Type
- Small Molecule
- Groups
- Approved
- Description
Dexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.
- Structure
Structure for DB00405 (Dexbrompheniramine)
- Synonyms
- (+)-Brompheniraminum
- (+)-parabromdylamine
- (R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine
- (S)-(+)-Brompheniramine
- (S)-Brompheniramine
- 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine
- D-Brompheniramine
- Desbrofeniramina
- Dexbromfeniramina
- Dexbrompheniramin
- Dexbromphéniramine
- Dexbrompheniraminum
- Parabromodylamine
- Product Ingredients
Ingredient UNII CAS InChI Key Dexbrompheniramine maleate BPA9UT29BS 2391-03-9 SRGKFVAASLQVBO-DASCVMRKSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Ala-hist Ir Tablet 2 mg/1 Oral Poly Pharmaceuticals 2011-08-22 Not applicable US 
PediaVent Tablet, chewable 1 mg/1 Oral Carwin Associates, Inc 2014-08-05 Not applicable US PediaVent Syrup 2 mg/5mL Oral Carwin Associates, Inc 2014-08-04 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acticon Dexbrompheniramine maleate (2 mg/1) + Pseudoephedrine hydrochloride (60 mg/1) Tablet Oral Actipharma, Inc 2015-08-13 Not applicable US Acticon Dexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Actipharma, Inc 2016-07-14 Not applicable US Actidogesic Dexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1) Tablet Oral Actipharma, Inc 2016-10-14 Not applicable US Ala-hist PE Dexbrompheniramine maleate (2 mg/1) + Phenylephrine hydrochloride (10 mg/1) Tablet Oral Poly Pharmaceuticals 2011-09-15 Not applicable US Alahist CF Dexbrompheniramine maleate (2 g/1) + Dextromethorphan hydrobromide (20 g/1) + Phenylephrine hydrochloride (10 g/1) Tablet Oral Poly Pharmaceuticals 2017-09-14 Not applicable US Alahistdm DM Dexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL) + Phenylephrine hydrochloride (7.5 mg/5mL) Liquid Oral Poly Pharmaceuticals 2016-09-01 Not applicable US Bio-cnex Dexbrompheniramine maleate (1 mg/5mL) + Pseudoephedrine hydrochloride (30 mg/5mL) Liquid Oral Advanced Generic Corporation 2017-01-01 Not applicable US Biogesic Dexbrompheniramine maleate (1 mg/1) + Acetaminophen (500 mg/1) Tablet Oral Advanced Generic Corporation 2017-01-01 Not applicable US Bionatuss DXP Dexbrompheniramine maleate (2 mg/5mL) + Dextromethorphan hydrobromide (20 mg/5mL) + Phenylephrine hydrochloride (10 mg/5mL) Liquid Oral Advanced Generic Corporation 2009-10-01 Not applicable US Chlo Hist Dexbrompheniramine maleate (1 mg/5mL) + Chlophedianol hydrochloride (12.5 mg/5mL) Liquid Oral R. A. Mc Neil Company 2014-09-15 Not applicable US - International/Other Brands
- Disophrol (Schering) / Drixoral (Schering )
- Categories
- UNII
- 75T64B71RP
- CAS number
- 132-21-8
- Weight
- Average: 319.239
Monoisotopic: 318.073161265 - Chemical Formula
- C16H19BrN2
- InChI Key
- ZDIGNSYAACHWNL-HNNXBMFYSA-N
- InChI
- InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1
- IUPAC Name
- [(3S)-3-(4-bromophenyl)-3-(pyridin-2-yl)propyl]dimethylamine
- SMILES
- CN(C)CC[C@@H](C1=CC=C(Br)C=C1)C1=CC=CC=N1
Pharmacology
- Indication
For treatment and relief of symptoms of allergies, hay fever, and colds
- Associated Conditions
- Pharmacodynamics
In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Dexbrompheniramine is a histamine H1 antagonist (or more correctly, an inverse histamine agonist) of the alkylamine class. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
- Mechanism of action
Dexbrompheniramine competitively binds to the histamine H1-receptor. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Target Actions Organism AHistamine H1 receptor antagonistHuman - Absorption
Antihistamines are well absorbed from the gastrointestinal tract after oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Hepatic (cytochrome P-450 system), some renal.
- Route of elimination
- Not Available
- Half life
25 hours
- Clearance
- Not Available
- Toxicity
Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Dexbrompheniramine H1-Antihistamine Action Drug action Dexbrompheniramine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental, Illicit 4-Methoxyamphetamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 4-Methoxyamphetamine. Experimental, Illicit 5-methoxy-N,N-dimethyltryptamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 5-methoxy-N,N-dimethyltryptamine. Experimental, Illicit 7-Nitroindazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 7-Nitroindazole. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Experimental Abexinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Abexinostat. Investigational Acepromazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Aceprometazine. Approved Acetazolamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetazolamide. Approved, Vet Approved Acetophenazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetophenazine. Approved Acetylglycinamide chloral hydrate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Acetylglycinamide chloral hydrate. Experimental Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Dexbrompheniramine. Approved Adinazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Adinazolam. Approved Adipiplon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alaproclate. Experimental Alcaftadine The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Dexbrompheniramine. Approved Alcuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alcuronium. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Dexbrompheniramine. Approved, Illicit Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Dexbrompheniramine. Approved, Investigational Alimemazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alimemazine. Approved, Vet Approved Allobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Allobarbital. Experimental Allopregnanolone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Allopregnanolone. Investigational Almotriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Almotriptan. Approved, Investigational Alosetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alosetron. Approved, Withdrawn Alphacetylmethadol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Alprenolol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alprenolol. Approved, Withdrawn Alverine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Alverine. Approved, Investigational Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Dexbrompheniramine. Approved Amifampridine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amifampridine. Approved Amikacin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amikacin. Approved, Investigational, Vet Approved Amineptine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amineptine. Illicit, Withdrawn Amiodarone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Amitriptyline. Approved Amitriptylinoxide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amitriptylinoxide. Approved, Investigational Amobarbital The risk or severity of adverse effects can be increased when Amobarbital is combined with Dexbrompheniramine. Approved, Illicit Amodiaquine The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Dexbrompheniramine. Approved, Investigational Amoxapine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Amperozide. Experimental Amphetamine Amphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit, Investigational Anagrelide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Anagrelide. Approved Aniracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aniracetam. Experimental Antazoline The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Antazoline. Approved APD791 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with APD791. Investigational Apomorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apomorphine. Approved, Investigational Apramycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apramycin. Experimental, Vet Approved Aprobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aprobarbital. Approved, Illicit Apronalide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apronalide. Experimental Arbaclofen Placarbil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Arbaclofen Placarbil. Investigational Arbekacin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Arbekacin. Approved, Investigational Arformoterol The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Dexbrompheniramine. Approved, Investigational Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine. Approved, Investigational Aripiprazole lauroxil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aripiprazole lauroxil. Approved, Investigational Arsenic trioxide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Arsenic trioxide. Approved, Investigational Artemether The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Artemether. Approved Asenapine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Asenapine. Approved Astemizole The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Astemizole. Approved, Withdrawn Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Dexbrompheniramine. Approved, Investigational Atomoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atomoxetine. Approved Atracurium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atracurium. Approved, Experimental, Investigational Atracurium besylate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atracurium besylate. Approved Azaperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Azaperone. Investigational, Vet Approved Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Dexbrompheniramine. Approved AZD-3043 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with AZD-3043. Investigational Azelastine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azithromycin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Dexbrompheniramine. Approved Barbexaclone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbexaclone. Experimental Barbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Barbital. Illicit Beclamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Beclamide. Experimental Bedaquiline The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Bedaquiline. Approved Bekanamycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bekanamycin. Experimental Benactyzine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benactyzine. Withdrawn Benmoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benmoxin. Withdrawn Benperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benperidol. Approved, Investigational Benzatropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Dexbrompheniramine. Approved Benzoctamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzoctamine. Approved Benzphetamine Benzphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzyl alcohol. Approved Benzylpenicilloyl Polylysine Dexbrompheniramine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Bepridil The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Bepridil. Approved, Withdrawn Besifloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Besifloxacin. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexbrompheniramine. Approved, Investigational Bifemelane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bifemelane. Experimental Bifeprunox The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bifeprunox. Investigational Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Dexbrompheniramine. Approved, Investigational BL-1020 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with BL-1020. Investigational Blonanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Blonanserin. Approved, Investigational Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dexbrompheniramine. Approved, Investigational Botulinum Toxin Type A The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Botulinum Toxin Type B. Approved, Investigational Brexpiprazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Brivaracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brivaracetam. Approved, Investigational Brofaromine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brofaromine. Experimental Bromazepam The risk or severity of adverse effects can be increased when Bromazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromocriptine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Brotizolam. Approved, Investigational, Withdrawn Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Dexbrompheniramine. Approved Bufotenine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bufotenine. Experimental, Illicit Buprenorphine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bupropion. Approved Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Dexbrompheniramine. Approved, Investigational Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Dexbrompheniramine. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine. Approved, Illicit Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Dexbrompheniramine. Approved, Illicit Butaperazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butaperazine. Experimental Butethal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine. Approved, Illicit, Vet Approved Butriptyline The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Butriptyline. Approved Cabergoline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cabergoline. Approved Camazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Camazepam. Approved, Illicit Cannabidiol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cannabidiol. Approved, Investigational Cannabidivarin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cannabidivarin. Investigational Capreomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Capreomycin. Approved Captodiame The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Captodiame. Approved, Investigational Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine. Approved, Investigational Carbinoxamine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Carbinoxamine. Approved Carbromal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carbromal. Experimental Carfentanil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carfentanil. Illicit, Investigational, Vet Approved Cariprazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cariprazine. Approved, Investigational Carisbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Carisbamate. Investigational Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine. Approved Caroxazone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Caroxazone. Withdrawn Cathinone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cathinone. Illicit Ceritinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ceritinib. Approved Cerlapirdine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cerlapirdine. Investigational Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Dexbrompheniramine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Dexbrompheniramine. Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dexbrompheniramine. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroquine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chloroquine. Approved, Investigational, Vet Approved Chlorphenamine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorphenamine. Approved Chlorphenesin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorphentermine Chlorphentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Illicit, Withdrawn Chlorproethazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorproethazine. Experimental Chlorpromazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlortetracycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Chlortetracycline. Approved, Investigational, Vet Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine. Approved Cilansetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cilansetron. Investigational Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Dexbrompheniramine. Approved, Investigational Cinitapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cinitapride. Approved, Investigational Cinnarizine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinnarizine. Approved, Investigational Cinolazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cinolazepam. Approved Cinoxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cinoxacin. Approved, Investigational, Withdrawn Ciprofloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ciprofloxacin. Approved, Investigational Cisapride The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cisapride. Approved, Investigational, Withdrawn Cisatracurium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cisatracurium. Approved Citalopram The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Citalopram. Approved Clarithromycin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clarithromycin. Approved Clemastine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clidinium. Approved Clindamycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clindamycin. Approved, Vet Approved Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Dexbrompheniramine. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with clomethiazole. Investigational Clomipramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clomipramine. Approved, Investigational, Vet Approved Clomocycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clomocycline. Approved Clonazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Dexbrompheniramine. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clothiapine. Experimental Clotiazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Clotiazepam. Approved, Illicit Cloxazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cloxazolam. Approved, Investigational Clozapine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Clozapine. Approved Cocaine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine. Approved, Illicit Colistimethate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Colistimethate. Approved, Vet Approved Colistin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Colistin. Approved Crizotinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Crizotinib. Approved CUDC-101 The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with CUDC-101. Investigational CUDC-907 The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Dexbrompheniramine. Investigational Cyamemazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyamemazine. Approved Cyclizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclizine. Approved Cyclobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclobarbital. Experimental Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclopropane. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Cyproheptadine. Approved Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Dexbrompheniramine. Approved, Investigational Dantrolene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dapoxetine. Investigational Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Dexbrompheniramine. Approved, Investigational Deanol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Deanol. Experimental Decamethonium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Decamethonium. Approved Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Dexbrompheniramine. Approved Delamanid The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Delamanid. Approved, Investigational Delorazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Delorazepam. Approved, Illicit, Investigational Demeclocycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Demeclocycline. Approved Deramciclane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine. Approved Desipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Deutetrabenazine. Approved, Investigational Dexchlorpheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dexchlorpheniramine. Experimental, Investigational Dexchlorpheniramine maleate The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dexchlorpheniramine maleate. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dexmedetomidine. Approved, Vet Approved Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dexmethylphenidate. Approved, Investigational Dextofisopam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextofisopam. Investigational Dextroamphetamine Dextroamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational, Vet Approved Dibekacin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dibekacin. Experimental Dibenzepin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dibenzepin. Experimental Dichloralphenazone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dichloralphenazone. Approved, Illicit Diethyl ether The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Diethyl ether. Experimental Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit Difenoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Difenoxin. Approved, Illicit Difloxacin The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Dexbrompheniramine. Vet Approved Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dexbrompheniramine. Approved, Illicit Dihydroergotamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydromorphine. Experimental, Illicit Dihydrostreptomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dihydrostreptomycin. Investigational, Vet Approved Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dimenhydrinate. Approved Dimetacrine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimetacrine. Approved, Withdrawn Dimethyltryptamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dimethyltryptamine. Experimental, Illicit Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dexbrompheniramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dexbrompheniramine. Approved, Illicit Disopyramide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Disopyramide. Approved Dixyrazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dixyrazine. Experimental Dofetilide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dofetilide. Approved, Investigational Dolasetron The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dolasetron. Approved, Investigational Domoic Acid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Domoic Acid. Experimental Domperidone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Domperidone. Approved, Investigational, Vet Approved Donepezil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Donepezil. Approved Dopamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dopamine. Approved Doramectin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doramectin. Vet Approved Dosulepin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dosulepin. Approved Dotarizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dotarizine. Investigational Doxacurium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxacurium. Approved Doxefazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxefazepam. Experimental Doxepin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxepin. Approved, Investigational Doxycycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Illicit Dronedarone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dyclonine. Approved Ebastine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ebastine. Approved, Investigational Ecopipam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ecopipam. Investigational Edivoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Edivoxetine. Investigational Efavirenz The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz. Approved, Investigational Eletriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eletriptan. Approved, Investigational Eliglustat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eltanolone. Investigational Eltoprazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eltoprazine. Investigational Emedastine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Emedastine. Approved Emepronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Emepronium. Experimental Emylcamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Emylcamate. Experimental Enflurane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Enflurane. Approved, Investigational, Vet Approved Enoxacin The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Dexbrompheniramine. Approved, Investigational Entacapone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Entacapone. Approved, Investigational Entinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Entinostat. Investigational Eperisone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eperisone. Approved, Investigational Epinastine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Epinastine. Approved, Investigational Eplivanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eplivanserin. Investigational Ergoloid mesylate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergoloid mesylate. Approved Ergonovine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergonovine. Approved Ergotamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ergotamine. Approved Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dexbrompheniramine. Approved, Investigational Erlotinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erlotinib. Approved, Investigational Erythromycin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Escitalopram. Approved, Investigational Eslicarbazepine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine. Approved Eslicarbazepine acetate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Eslicarbazepine acetate. Approved Esmirtazapine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Esmirtazapine. Investigational Esreboxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Esreboxetine. Investigational Estazolam The risk or severity of adverse effects can be increased when Estazolam is combined with Dexbrompheniramine. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Dexbrompheniramine. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etacrynic acid. Approved, Investigational Ethadione The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethadione. Experimental Ethanol Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ethylmorphine. Approved, Illicit Etifoxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etifoxine. Investigational, Withdrawn Etiracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etiracetam. Investigational Etizolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ezogabine. Approved, Investigational Fabomotizole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fabomotizole. Experimental Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Dexbrompheniramine. Approved Fazadinium bromide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fazadinium bromide. Experimental Febarbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Febarbamate. Experimental Felbamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenfluramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenfluramine. Approved, Illicit, Investigational, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Dexbrompheniramine. Approved, Illicit, Investigational, Vet Approved Fenyramidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fenyramidol. Experimental Fexofenadine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fexofenadine. Approved, Investigational Fingolimod The risk or severity of QTc prolongation can be increased when Fingolimod is combined with Dexbrompheniramine. Approved, Investigational Flecainide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Flecainide. Approved, Withdrawn Fleroxacin The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Dexbrompheniramine. Approved Flibanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluanisone. Experimental Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Dexbrompheniramine. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fludiazepam. Approved, Illicit Flumequine The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dexbrompheniramine. Withdrawn Flunarizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Dexbrompheniramine. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluvoxamine. Approved, Investigational Formoterol The risk or severity of QTc prolongation can be increased when Formoterol is combined with Dexbrompheniramine. Approved, Investigational Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Dexbrompheniramine. Approved Fosphenytoin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fospropofol. Approved, Illicit, Investigational Framycetin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Framycetin. Approved Frovatriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Frovatriptan. Approved, Investigational Furazolidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Furazolidone. Approved, Investigational, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Dexbrompheniramine. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gabapentin Enacarbil. Approved, Investigational Gaboxadol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gaboxadol. Investigational Gadobenic acid The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gadobenic acid. Approved, Investigational Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dexbrompheniramine. Approved Gallamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gallamine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gallamine Triethiodide. Approved Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dexbrompheniramine. Approved, Illicit, Investigational Gantacurium Chloride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gantacurium Chloride. Investigational Garenoxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Dexbrompheniramine. Approved, Investigational Gedocarnil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gedocarnil. Experimental Gemifloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Gemifloxacin. Approved, Investigational Geneticin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Geneticin. Experimental Gentamicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gentamicin. Approved, Vet Approved GENTAMICIN C1A The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with GENTAMICIN C1A. Experimental Gepefrine Gepefrine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental Gepirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Gepirone. Investigational Givinostat The risk or severity of QTc prolongation can be increased when Givinostat is combined with Dexbrompheniramine. Investigational Glutethimide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Glutethimide. Approved, Illicit Goserelin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Goserelin. Approved Granisetron The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Granisetron. Approved, Investigational Grepafloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guanfacine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halazepam. Approved, Illicit, Withdrawn Halofantrine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Halofantrine. Approved Haloperidol The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane. Approved, Vet Approved Harmaline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Harmaline. Experimental Heptabarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Heptabarbital. Approved Heroin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Heroin. Approved, Illicit, Investigational Hexafluronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexafluronium. Approved Hexamethonium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexamethonium. Experimental Hexapropymate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexapropymate. Experimental Hexobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hexobarbital. Approved Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Dexbrompheniramine. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine. Approved, Investigational Hydracarbazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hydracarbazine. Experimental Hydrocodone Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Dexbrompheniramine. Approved, Illicit Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Dexbrompheniramine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Hygromycin B The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hygromycin B. Vet Approved Hypericin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hypericin. Investigational Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dexbrompheniramine. Approved, Investigational Ibutilide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ibutilide. Approved Idalopirdine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Idalopirdine. Investigational Ifenprodil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ifenprodil. Approved, Investigational, Withdrawn Iferanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iferanserin. Investigational Iloperidone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Iloperidone. Approved Imagabalin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imagabalin. Investigational Imatinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imatinib. Approved Imipramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imipramine. Approved Imipramine oxide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine oxide. Experimental Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Dexbrompheniramine. Approved Indalpine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indalpine. Investigational, Withdrawn Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Dexbrompheniramine. Approved Indiplon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Indiplon. Investigational Iofetamine I-123 Iofetamine I-123 may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved Iprazochrome The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iprazochrome. Experimental Iprindole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iprindole. Experimental Iproclozide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iproclozide. Withdrawn Iproniazid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iproniazid. Withdrawn Isepamicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Isepamicin. Experimental Isocarboxazid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Dexbrompheniramine. Approved, Vet Approved Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Dexbrompheniramine. Approved, Investigational Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Dexbrompheniramine. Approved, Investigational Ivabradine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivabradine. Approved Ivosidenib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ivosidenib. Approved, Investigational Kanamycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Kanamycin. Approved, Investigational, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine. Approved, Vet Approved Ketanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketanserin. Investigational Ketazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ketobemidone. Approved, Investigational Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Dexbrompheniramine. Approved, Investigational Ketotifen The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ketotifen. Approved L-Tryptophan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with L-Tryptophan. Approved, Nutraceutical, Withdrawn Lacosamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lacosamide. Approved Lamotrigine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lamotrigine. Approved, Investigational Lanicemine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lanicemine. Investigational Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Dexbrompheniramine. Approved, Investigational Lasmiditan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lasmiditan. Investigational Lenvatinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lenvatinib. Approved, Investigational Leuprolide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levetiracetam. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levodopa. Approved Levofloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin. Approved, Investigational Levomethadyl Acetate The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Dexbrompheniramine. Approved Lincomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lincomycin. Approved, Vet Approved Linezolid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Linezolid. Approved, Investigational Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lisuride. Approved, Investigational Lithium carbonate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lithium carbonate. Approved Lithium cation The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lithium cation. Experimental Lofentanil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lofentanil. Illicit Lofepramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lofepramine. Experimental Lofexidine The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Lofexidine. Approved, Investigational Lomefloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lomefloxacin. Approved, Investigational Lopinavir The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Loprazolam. Experimental Loratadine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Dexbrompheniramine. Approved Lorcaserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lorcaserin. Approved Lormetazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lormetazepam. Approved Lorpiprazole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lorpiprazole. Approved Lortalamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lortalamine. Experimental Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine. Approved Lumateperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lumateperone. Investigational Lumefantrine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine. Approved, Investigational Lymecycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lymecycline. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Lysergic Acid Diethylamide. Illicit, Investigational, Withdrawn m-Chlorophenylpiperazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with m-Chlorophenylpiperazine. Investigational Macimorelin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Macimorelin. Approved, Investigational Magnesium acetate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium acetate. Approved Magnesium acetate tetrahydrate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium acetate tetrahydrate. Approved Magnesium Aluminum Silicate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Aluminum Silicate. Approved Magnesium aspartate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium aspartate. Experimental Magnesium carbonate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium carbonate. Approved, Investigational Magnesium cation The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium cation. Approved, Nutraceutical Magnesium chloride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium chloride. Approved Magnesium citrate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium citrate. Approved Magnesium gluconate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium gluconate. Approved, Investigational Magnesium glycinate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium glycinate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium hydroxide. Approved, Investigational Magnesium orotate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium orotate. Experimental Magnesium oxide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium oxide. Approved Magnesium phosphate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium phosphate. Experimental Magnesium silicate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium silicate. Approved Magnesium stearate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium stearate. Investigational Magnesium sulfate The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Magnesium Trisilicate. Approved Maprotiline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline. Approved, Investigational Mazindol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mazindol. Approved, Investigational Mebanazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebanazine. Withdrawn Mebicar The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebicar. Experimental Mebutamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mebutamate. Approved Mecamylamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mecamylamine. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medetomidine. Vet Approved Medifoxamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Medifoxamine. Experimental Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Dexbrompheniramine. Approved, Investigational Melatonin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melitracen The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melitracen. Experimental, Investigational Melperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Melperone. Approved, Investigational Mephedrone Mephedrone may decrease the sedative and stimulatory activities of Dexbrompheniramine. Investigational Mephenesin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenesin. Approved Mephenoxalone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenoxalone. Experimental Mephentermine Mephentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved Mephenytoin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mephenytoin. Investigational, Withdrawn Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Meptazinol. Experimental Mepyramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mepyramine. Approved, Vet Approved Mequitazine The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Dexbrompheniramine. Approved Mesoridazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone. Approved Metergoline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metergoline. Experimental Methacycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methacycline. Approved, Investigational Methadone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methadyl Acetate. Approved, Illicit Methamphetamine Methamphetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methaqualone. Illicit, Withdrawn Metharbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metharbital. Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine. Approved Methotrimeprazine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methoxyphenamine Methoxyphenamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental Methsuximide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide. Approved Methylene blue The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylene blue. Approved, Investigational Methylpentynol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylpentynol. Experimental Methylphenidate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylphenidate. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methylphenobarbital. Approved Methyprylon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methyprylon. Approved, Illicit, Withdrawn Methysergide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methysergide. Approved Metoclopramide The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Dexbrompheniramine. Approved, Investigational Metocurine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metocurine. Approved Metocurine Iodide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metocurine Iodide. Approved, Withdrawn Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Dexbrompheniramine. Approved Metyrosine Dexbrompheniramine may increase the sedative activities of Metyrosine. Approved Mianserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mianserin. Approved, Investigational Micronomicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Micronomicin. Experimental Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine. Approved, Illicit Midomafetamine Midomafetamine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental, Illicit, Investigational Mifepristone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mifepristone. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Milnacipran. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Minaprine. Approved Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Investigational Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Dexbrompheniramine. Approved Mirtazapine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mivacurium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mivacurium. Approved MK-212 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with MK-212. Investigational MMDA MMDA may decrease the sedative and stimulatory activities of Dexbrompheniramine. Experimental, Illicit Mocetinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Mocetinostat. Investigational Moclobemide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moclobemide. Approved, Investigational Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Dexbrompheniramine. Approved Molindone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Molindone. Approved Moperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moperone. Experimental Moricizine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Moricizine. Approved, Investigational, Withdrawn Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Dexbrompheniramine. Approved, Investigational Mosapramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mosapramine. Experimental Mosapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Mosapride. Investigational Moxifloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin. Approved, Investigational MRK-409 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with MRK-409. Experimental N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine. Experimental Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved, Investigational Naftidrofuryl The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naftidrofuryl. Experimental Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Dexbrompheniramine. Approved Nalidixic Acid The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nalidixic Acid. Approved, Investigational Naluzotan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naluzotan. Investigational Naratriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naratriptan. Approved, Investigational Naronapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naronapride. Investigational Neamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neamine. Experimental Nefazodone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefazodone. Approved, Withdrawn Nefiracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nefiracetam. Investigational Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Dexbrompheniramine. Approved Nemonoxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nemonoxacin. Investigational Neocitrullamon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neocitrullamon. Experimental Neomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neomycin. Approved, Vet Approved Neosaxitoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Neosaxitoxin. Investigational Netilmicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Netilmicin. Approved, Investigational Nialamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nialamide. Withdrawn Niaprazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Niaprazine. Experimental Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Dexbrompheniramine. Approved, Investigational Nilotinib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Nilotinib. Approved, Investigational Nisoxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nisoxetine. Experimental Nitrazepam The risk or severity of adverse effects can be increased when Nitrazepam is combined with Dexbrompheniramine. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dexbrompheniramine. Approved, Vet Approved Nomifensine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nomifensine. Withdrawn Nordazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nordazepam. Approved Norfloxacin The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Dexbrompheniramine. Approved Normethadone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Nortriptyline. Approved Octamoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Octamoxin. Withdrawn Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Dexbrompheniramine. Approved, Investigational Ofloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ofloxacin. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Dexbrompheniramine. Approved, Investigational Olodaterol The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Dexbrompheniramine. Approved Olopatadine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Olopatadine. Approved Ondansetron The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ondansetron. Approved Opipramol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Opipramol. Investigational Opium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Opium. Approved, Illicit Orbifloxacin The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Dexbrompheniramine. Vet Approved Orphenadrine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Orvepitant The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Orvepitant. Investigational Osanetant The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Osanetant. Investigational Oxaflozane The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaflozane. Experimental Oxaliplatin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin. Approved, Investigational Oxaprotiline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxaprotiline. Experimental Oxatomide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxatomide. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine. Approved Oxcarbazepine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxcarbazepine. Approved Oxiracetam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxiracetam. Experimental Oxitriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxitriptan. Approved, Investigational, Nutraceutical Oxolinic acid The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Dexbrompheniramine. Experimental Oxprenolol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxprenolol. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Dexbrompheniramine. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Oxypertine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxypertine. Experimental Oxytetracycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Oxytetracycline. Approved, Investigational, Vet Approved Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Dexbrompheniramine. Approved, Vet Approved Paliperidone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Paliperidone. Approved Palonosetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Palonosetron. Approved, Investigational Pancuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pancuronium. Approved Panobinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Panobinostat. Approved, Investigational Papaverine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Papaverine. Approved, Investigational Paraldehyde Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paramethadione The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paramethadione. Approved Pargyline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pargyline. Approved Paromomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine. Approved, Investigational Pasireotide The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Dexbrompheniramine. Approved Pazopanib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pazopanib. Approved Pazufloxacin The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Dexbrompheniramine. Investigational Pefloxacin The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Dexbrompheniramine. Approved Penbutolol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penbutolol. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penfluridol. Experimental Penimepicycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Penimepicycline. Experimental Pentamidine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pentamidine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Dexbrompheniramine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Perazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perazine. Approved, Investigational Perflutren The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Perflutren. Approved Pergolide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pergolide. Approved, Investigational, Vet Approved, Withdrawn Perospirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Dexbrompheniramine. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Dexbrompheniramine. Approved Phenacemide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenacemide. Approved Phenazocine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenazocine. Experimental Phencyclidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phencyclidine. Illicit Phenelzine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenelzine. Approved Phenethylamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenethylamine. Experimental Pheneturide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pheneturide. Experimental Phenibut The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenibut. Experimental Pheniprazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pheniprazine. Withdrawn Pheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pheniramine. Approved Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Dexbrompheniramine. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoperidine. Experimental Phenoxypropazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenoxypropazine. Withdrawn Phenprobamate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phenprobamate. Experimental Phensuximide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Phensuximide. Approved Phentermine Phentermine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved, Illicit Phenytoin The risk or severity of adverse effects can be increased when Phenytoin is combined with Dexbrompheniramine. Approved, Vet Approved Piclozotan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piclozotan. Investigational Pimavanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pimavanserin. Approved, Investigational Pimozide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pimozide. Approved Pinazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pinazepam. Experimental Pindolol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipamperone. Approved, Investigational Pipecuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipecuronium. Approved Pipemidic acid The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Dexbrompheniramine. Experimental Pipotiazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piritramide. Approved, Investigational Pirlimycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pirlimycin. Vet Approved Pirlindole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pirlindole. Approved Piromidic acid The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Dexbrompheniramine. Experimental Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Dexbrompheniramine. Approved, Investigational Pivagabine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pivagabine. Investigational Pivhydrazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pivhydrazine. Withdrawn Pizotifen The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pizotifen. Approved Plazomicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Plazomicin. Approved, Investigational Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Polymyxin B Sulfate. Approved, Vet Approved Pomalidomide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide. Approved Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Pracinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Pracinostat. Investigational Pramipexole Dexbrompheniramine may increase the sedative activities of Pramipexole. Approved, Investigational Prazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Dexbrompheniramine can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Pridinol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pridinol. Experimental Primaquine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Primaquine. Approved Primidone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Primidone. Approved, Vet Approved Probucol The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Probucol. Approved, Investigational Procainamide The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Procainamide. Approved Procaine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procaine. Approved, Investigational, Vet Approved Procarbazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Procarbazine. Approved, Investigational Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine. Approved, Vet Approved Progabide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Progabide. Approved, Investigational Promazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine. Approved, Investigational Propafenone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propanidid. Experimental Propericiazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propericiazine. Approved, Investigational Propiomazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propiomazine. Approved Propiopromazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Propiopromazine. Vet Approved Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Dexbrompheniramine. Approved, Investigational, Vet Approved Prothipendyl The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Prothipendyl. Investigational Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine. Approved Proxibarbal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Proxibarbal. Experimental Prulifloxacin The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Dexbrompheniramine. Investigational PRX-08066 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with PRX-08066. Investigational Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Dexbrompheniramine. Approved Psilocybine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Psilocybine. Investigational Puromycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Puromycin. Experimental Pyrantel The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pyrantel. Approved, Vet Approved Pyrithyldione The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pyrithyldione. Experimental Quazepam The risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine. Approved, Illicit Quetiapine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quetiapine. Approved Quinidine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinidine. Approved, Investigational Quinine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Quinine. Approved Quinupramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Quinupramine. Experimental Raclopride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon. Approved, Investigational Ramosetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramosetron. Approved, Investigational Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Dexbrompheniramine. Approved, Investigational Rapacuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rapacuronium. Withdrawn Rasagiline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rasagiline. Approved Reboxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Reboxetine. Approved, Investigational Remacemide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remacemide. Investigational Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine. Approved Remoxipride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Remoxipride. Approved, Withdrawn Renzapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Renzapride. Investigational Repinotan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Repinotan. Investigational Reposal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Reposal. Approved Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Dexbrompheniramine. Approved, Investigational Ribociclib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ribociclib. Approved, Investigational Ribostamycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ribostamycin. Approved, Investigational Ricolinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ricolinostat. Investigational Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Dexbrompheniramine. Approved Riluzole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Riluzole. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ritanserin. Investigational Ritobegron Ritobegron may decrease the sedative and stimulatory activities of Dexbrompheniramine. Investigational Ritonavir The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Dexbrompheniramine. Approved, Investigational Rizatriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rizatriptan. Approved Rocuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rocuronium. Approved Rolipram The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rolipram. Investigational Rolitetracycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Rolitetracycline. Approved Romidepsin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Romidepsin. Approved, Investigational Romifidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Romifidine. Vet Approved Ropinirole Dexbrompheniramine may increase the sedative activities of Ropinirole. Approved, Investigational Rosoxacin The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Dexbrompheniramine. Approved, Investigational Rotigotine Dexbrompheniramine may increase the sedative activities of Rotigotine. Approved Roxithromycin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Roxithromycin. Approved, Investigational, Withdrawn RP-5063 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with RP-5063. Investigational Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Dexbrompheniramine. Approved Rufloxacin The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Dexbrompheniramine. Experimental Rupatadine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Rupatadine. Approved Safinamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Safinamide. Approved, Investigational Safrazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Safrazine. Withdrawn Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Dexbrompheniramine. Approved, Vet Approved Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexbrompheniramine. Approved Saquinavir The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Saquinavir. Approved, Investigational Sarafloxacin The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Dexbrompheniramine. Vet Approved, Withdrawn Saredutant The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Saredutant. Investigational Sarpogrelate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sarpogrelate. Investigational Scopolamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Selegiline. Approved, Investigational, Vet Approved Serotonin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Serotonin. Investigational, Nutraceutical Sertindole The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine. Approved, Vet Approved Sibutramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sibutramine. Approved, Illicit, Investigational, Withdrawn Sisomicin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sisomicin. Investigational Sitafloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sitafloxacin. Experimental, Investigational Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Dexbrompheniramine. Approved Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Dexbrompheniramine. Approved, Investigational Sotalol The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sotalol. Approved Sparfloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sparfloxacin. Approved, Investigational St. John's Wort The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Stiripentol. Approved Streptomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Streptomycin. Approved, Vet Approved Styramate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Styramate. Experimental Succinylcholine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Succinylcholine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine. Approved, Investigational Sulfamethoxazole The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Dexbrompheniramine. Approved Sulfisoxazole The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sulpiride. Approved, Investigational Sulthiame The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sulthiame. Experimental Sultopride The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sumatriptan. Approved, Investigational Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Dexbrompheniramine. Approved, Investigational Suvorexant Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Talbutal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Talbutal. Approved, Illicit Talopram The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Talopram. Experimental Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Dexbrompheniramine. Approved Tandospirone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tandospirone. Investigational Tandutinib The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Dexbrompheniramine. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine. Approved Tasimelteon The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tasimelteon. Approved, Investigational TD-8954 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with TD-8954. Investigational Technetium Tc-99m ciprofloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Technetium Tc-99m ciprofloxacin. Investigational Tedizolid phosphate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tedizolid phosphate. Approved Tegaserod The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tegaserod. Approved, Investigational, Withdrawn Telavancin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Telavancin. Approved Telithromycin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Telithromycin. Approved Temafloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Temafloxacin. Withdrawn Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Dexbrompheniramine. Approved, Investigational Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Dexbrompheniramine. Approved Terfenadine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terfenadine. Approved, Withdrawn Terlipressin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terlipressin. Approved, Investigational Terodiline The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Terodiline. Experimental Tetrabenazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tetrabenazine. Approved, Investigational Tetracycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetracycline. Approved, Vet Approved Tetrahydrocannabivarin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydrocannabivarin. Investigational Tetrahydropalmatine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrahydropalmatine. Investigational Tetrazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrazepam. Experimental Tetrodotoxin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tetrodotoxin. Investigational Thalidomide Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiamylal. Approved, Vet Approved Thiazinam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiazinam. Experimental Thiethylperazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiethylperazine. Withdrawn Thiocolchicoside The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiocolchicoside. Approved, Investigational Thiopental The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiopental. Approved, Vet Approved Thiopropazate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiopropazate. Experimental Thioproperazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thioproperazine. Approved Thioridazine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Thiothixene is combined with Dexbrompheniramine. Approved Tiagabine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine. Approved, Investigational Tianeptine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tianeptine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiapride. Approved, Investigational Tigecycline The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tigecycline. Approved Tiletamine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tizanidine. Approved, Investigational Tobramycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tobramycin. Approved, Investigational Tofisopam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tofisopam. Approved Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Dexbrompheniramine. Approved, Withdrawn Toloxatone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Toloxatone. Approved Tolperisone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tolperisone. Approved, Investigational Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Dexbrompheniramine. Approved, Investigational Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Dexbrompheniramine. Approved Toremifene The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Toremifene. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine. Approved, Investigational Tramiprosate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tramiprosate. Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trazodone. Approved, Investigational Treprostinil The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Dexbrompheniramine. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Dexbrompheniramine. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trichloroethylene. Approved Triclofos The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triclofos. Withdrawn Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexbrompheniramine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triflupromazine. Approved, Vet Approved Trimethadione The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimethadione. Approved Trimethoprim The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Dexbrompheniramine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Triprolidine. Approved Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Dexbrompheniramine. Approved, Vet Approved Tropisetron The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tropisetron. Approved, Investigational Trovafloxacin The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tubocurarine. Approved Tucidinostat The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Tucidinostat. Investigational Urapidil The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Urapidil. Investigational Vabicaserin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vabicaserin. Investigational Valerian The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valerian. Approved, Experimental, Investigational Valnoctamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valnoctamide. Investigational Valproic Acid The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic Acid. Approved, Investigational Valpromide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Valpromide. Experimental Vancomycin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vancomycin. Approved Vandetanib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Vandetanib. Approved Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Dexbrompheniramine. Approved Vecuronium The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vecuronium. Approved Vemurafenib The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Vemurafenib. Approved Venlafaxine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vigabatrin. Approved Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Dexbrompheniramine. Approved Vilazodone The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vilazodone. Approved Viloxazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Viloxazine. Approved, Investigational, Withdrawn Vinbarbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinbarbital. Experimental Vinpocetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinpocetine. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinyl ether. Experimental Vinylbital The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vinylbital. Experimental Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Dexbrompheniramine. Approved, Investigational Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dexbrompheniramine. Approved, Investigational Vortioxetine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vortioxetine. Approved, Investigational Wortmannin The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Wortmannin. Experimental XP19986 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with XP19986. Investigational Xylazine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Xylazine. Vet Approved YKP-1358 The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with YKP-1358. Investigational Yohimbine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zolmitriptan. Approved, Investigational Zolpidem Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Zopiclone is combined with Dexbrompheniramine. Approved Zotepine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014549
- PubChem Compound
- 16960
- PubChem Substance
- 46505186
- ChemSpider
- 16068
- ChEBI
- 59269
- ChEMBL
- CHEMBL1201287
- Therapeutic Targets Database
- DAP001068
- PharmGKB
- PA164746251
- Wikipedia
- Dexbrompheniramine
- ATC Codes
- R06AB56 — Dexbrompheniramine, combinations
- R06AB — Substituted alkylamines
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Packagers
- Poly Pharmaceuticals Inc.
- Dosage forms
Form Route Strength Tablet Oral 2 mg/1 Tablet Oral Tablet, extended release Oral Tablet; tablet, extended release Oral Liquid Oral Syrup Oral 2 mg/5mL Tablet, chewable Oral 1 mg/1 Syrup Oral - Prices
Unit description Cost Unit Ala-hist ir 2 mg tablet 0.82USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 113-115 US. Patent 3,030,371. logP 3.4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0127 mg/mL ALOGPS logP 3.63 ALOGPS logP 3.75 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 9.48 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 16.13 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 83.67 m3·mol-1 ChemAxon Polarizability 31.84 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9648 Blood Brain Barrier + 0.9576 Caco-2 permeable + 0.8867 P-glycoprotein substrate Substrate 0.6242 P-glycoprotein inhibitor I Non-inhibitor 0.8782 P-glycoprotein inhibitor II Non-inhibitor 0.93 Renal organic cation transporter Inhibitor 0.7955 CYP450 2C9 substrate Non-substrate 0.8345 CYP450 2D6 substrate Substrate 0.8346 CYP450 3A4 substrate Substrate 0.5898 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Inhibitor 0.8932 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8398 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7748 Ames test Non AMES toxic 0.9351 Carcinogenicity Non-carcinogens 0.9349 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 3.0758 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9121 hERG inhibition (predictor II) Inhibitor 0.7207
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0292-0940000000-f369442eba5344b3ecb4
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pheniramines
- Direct Parent
- Pheniramines
- Alternative Parents
- Bromobenzenes / Aralkylamines / Aryl bromides / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organobromides / Hydrocarbon derivatives
- Substituents
- Pheniramine / Bromobenzene / Halobenzene / Aralkylamine / Aryl bromide / Benzenoid / Monocyclic benzene moiety / Aryl halide / Heteroaromatic compound / Tertiary aliphatic amine
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- brompheniramine (CHEBI:59269)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- McLeod RL, Mingo G, O'Reilly S, Ruck LA, Bolser DC, Hey JA: Antitussive action of antihistamines is independent of sedative and ventilation activity in the guinea pig. Pharmacology. 1998 Aug;57(2):57-64. [PubMed:9691225]
- Bokesoy TA, Onaran HO: Atypical Schild plots with histamine H1 receptor agonists and antagonists in the rabbit aorta. Eur J Pharmacol. 1991 May 2;197(1):49-56. [PubMed:1680053]
- Onaran HO, Bokesoy TA: Kinetics of antagonism at histamine-H1 receptors in isolated rabbit arteries. Naunyn Schmiedebergs Arch Pharmacol. 1990 Apr;341(4):316-23. [PubMed:1970615]
- Yanni JM, Stephens DJ, Parnell DW, Spellman JM: Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol. 1994 Winter;10(4):665-75. [PubMed:7714410]
- Sadofsky LR, Campi B, Trevisani M, Compton SJ, Morice AH: Transient receptor potential vanilloid-1-mediated calcium responses are inhibited by the alkylamine antihistamines dexbrompheniramine and chlorpheniramine. Exp Lung Res. 2008 Dec;34(10):681-93. doi: 10.1080/01902140802339623. [PubMed:19085565]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:53